Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 37,800 shares, a decline of 49.5% from the March 31st total of 74,800 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 770,200 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Achilles Therapeutics

A hedge fund recently bought a new stake in Achilles Therapeutics stock. Vestal Point Capital LP acquired a new position in shares of Achilles Therapeutics plc (NASDAQ:ACHL) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 108,083 shares of the company’s stock, valued at approximately $96,000. Vestal Point Capital LP owned approximately 0.27% of Achilles Therapeutics as of its most recent SEC filing. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Stock Performance

ACHL stock opened at $0.76 on Friday. The company’s 50-day simple moving average is $1.11 and its 200 day simple moving average is $0.96. Achilles Therapeutics has a 52 week low of $0.74 and a 52 week high of $1.76. The company has a market capitalization of $30.31 million, a PE ratio of -0.44 and a beta of 1.09.

Achilles Therapeutics (NASDAQ:ACHL) last released its quarterly earnings results on Thursday, April 4th. The company reported ($0.46) EPS for the quarter. On average, analysts forecast that Achilles Therapeutics will post -1.34 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on ACHL shares. Chardan Capital decreased their price objective on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, April 5th. Piper Sandler reiterated a “neutral” rating and issued a $2.00 price objective (down from $8.00) on shares of Achilles Therapeutics in a report on Friday, April 5th.

About Achilles Therapeutics

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.